Chemical Procurement Quarterly

U.S. municipal water utilities procured an estimated $1.42 billion in treatment chemicals during Q2 2026, up roughly 7.4% year-over-year and meaningfully above the four-year linear trend. The increase is concentrated in two regulatory-driven lanes: orthophosphate corrosion control under the Lead and Copper Rule revisions (LCRR), and granular activated carbon (GAC) precursors under the federal PFAS MCL finalized in May 2025. Together those two lanes accounted for roughly 38 cents of every dollar of additional spend versus Q2 2025.

Sodium hypochlorite remains the largest single lane by spend at roughly $312 million for the quarter, but the growth story is in corrosion control: orthophosphate spend was up 19.6% year-over-year, with the steepest increases concentrated in the Mid-Atlantic and Great Lakes regions where LCRR-driven service-line replacements are pulling forward the chemical demand curve. The third headline lane, ferric chloride for coagulation, posted modest 3.1% growth as utilities held coagulation budgets steady while reallocating to the LCRR and PFAS lanes.

Sodium hypochlorite holds the top spot every quarter, and Q2 was no exception. The 4.2% YoY increase is roughly one third price-driven (caustic-side feedstock pressure carrying through generators) and two thirds volume-driven (more plants running secondary disinfection at lower free-chlorine residuals to manage disinfection byproducts under the Stage 2 D/DBP rule). Suppliers should expect this lane to grow at low-single-digits indefinitely; it is the steady cash-flow lane, not the growth lane.

Orthophosphate is the growth lane right now and is likely to stay that way through 2027. The Lead and Copper Rule revisions require utilities to demonstrate corrosion control during their service-line replacement programs, and most utilities have standardized on orthophosphate dosing as the corrosion-control method of choice. The 19.6% YoY increase reflects roughly 11 percentage points of incremental volume from utilities ramping into year two of their compliance schedules, plus 8 percentage points of price-and-mix from utilities switching to higher-purity formulations. Expect this growth rate to taper into single digits by 2028 once the bulk of utility programs are at steady state.

Ferric chloride and the broader coagulant lane (alum, polyaluminum chloride, ferric sulfate) is essentially flat in real terms. Coagulant budgets are sticky; utilities replace one coagulant with another more often than they grow the line item. The interesting movement here is share-of-wallet: ferric chloride gained roughly 2 percentage points of cross-coagulant share at alum's expense, driven by tightening turbidity standards that favor ferric's broader pH range. This is a substitution story, not a growth story.